Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection

SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, F Gutierrez, L Hocqueloux, F Maggiolo, U Sandkovsky, C Granier, K Pappa, B Wynne, S Min, G Nichols

Research output: Contribution to journalArticleAcademicpeer-review

562 Citations (Scopus)

Abstract

BackgroundDolutegravir (S/GSK1349572), a once-daily, unboosted integrase inhibitor, was recently approved in the United States for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. Dolutegravir, in combination with abacavir-lamivudine, may provide a simplified regimen. MethodsWe conducted a randomized, double-blind, phase 3 study involving adult participants who had not received previous therapy for HIV-1 infection and who had an HIV-1 RNA level of 1000 copies per milliliter or more. Participants were randomly assigned to dolutegravir at a dose of 50 mg plus abacavir-lamivudine once daily (DTG-ABC-3TC group) or combination therapy with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabine once daily (EFV-TDF-FTC group). The primary end point was the propo ResultsA total of 833 participants received at least one dose of study drug. At week 48, the proportion of participants with an HIV-1 RNA level of less than 50 copies per milliliter was significantly higher in the DTG-ABC-3TC group than in the EFV-TDF-FTC group (88% vs. 81%, P=0.003), thus meeting the criterion for superiority. The DTG-ABC-3TC group had a shorter median time to viral suppression than did the EFV-TDF-FTC group (28 vs. 84 days, P<0.001), as well as greater increases in CD4+ T-cell ConclusionsDolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015.)
Original languageUndefined/Unknown
Pages (from-to)1807-1818
Number of pages12
JournalNew England Journal of Medicine
Volume369
Issue number19
DOIs
Publication statusPublished - 2013
Externally publishedYes

Cite this